Adrenergic release inhibitor
Class of antihypertensive drugs
Adrenergic release inhibitors are a class of drugs which inhibit the release of epinephrine (adrenaline) and/or norepinephrine (noradrenaline) from adrenergic nerve terminals and are used as antihypertensives.[1][2] Examples of these agents include bethanidine, bretylium, debrisoquine, guanadrel, guanazodine, guancydine, guanethidine, guanoclor, and guanoxan.[1][2] Most agents of this class are guanidinium compounds and have little capacity to cross the blood–brain barrier.[2]
References
- ^ a b Lukas G (1973). "Metabolism and biochemical pharmacology of guanethidine and related compounds". Drug Metab Rev. 2 (1): 101–16. doi:10.3109/03602537409030007. PMID 4590229.
- ^ a b c Stokes, Gordon S.; Oates, Helen F. (1982). "Blockers of the Neuromuscular Junction as Antihypertensive Agents". Hypertensive Cardiovascular Disease: Pathophysiology and Treatment. Springer Netherlands. pp. 828–833. doi:10.1007/978-94-009-7476-0_51. ISSN 0166-9842.
- v
- t
- e
(antagonize α-adrenergic
vasoconstriction)
Central |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peripheral |
|
Serotonin receptor antagonists | |
---|---|
Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III